Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834753 · ClinicalTrials.gov registry record · Phase 3
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
A Phase 3 study of Age-related Macular Degeneration and Neovascular Age-related Macular Degeneration, sponsored by Outlook Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT03834753 is a Phase 3 study of Age-related Macular Degeneration and Neovascular Age-related Macular Degeneration that has completed, run by Outlook Therapeutics. The registered enrollment target is 228 participants, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT03834753, a Phase 3 study of Age-related Macular Degeneration and Neovascular Age-related Macular Degeneration, has completed, sponsored by Outlook Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
- BIOLOGICAL ranibizumab
Study Locations (20)
California
- Clinical Site - Arcadia
- Clinical Site - Beverly Hills
- Clinical Site - Campbell
- Clinical Site - Glendale
- Clinical Site - Laguna Hills
- Clinical Site - Long Beach
- Clinical Site - Mountain View
- Clinical Site - Oxnard
- Clinical Site - Palm Desert
- Clinical Site - Poway
- Clinical Site - Sacramento
- Clinical Site - Santa Maria
- Clinical Site - Tustin
Florida
- Clinical Site - Clearwater
- Clinical Site - Pinellas Park
- Clinical Site - Sarasota
- Clinical Site - Winter Haven
Arizona
- Clinical Site - Tucson
Colorado
- Clinical Site - Golden
Connecticut
- Clinical Site - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834753
The ClinicalTrials.gov registry entry for NCT03834753 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (85% lower). The listed sponsor is Outlook Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which bevacizumab is the first listed.
NCT03834753 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03834753 about?
NCT03834753 is a clinical study titled "A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)". This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
What is the current status of trial NCT03834753?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2019-06-25. Estimated completion is 2021-07-08.
What conditions does trial NCT03834753 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration.
What interventions are being tested in trial NCT03834753?
The interventions under investigation include: bevacizumab (BIOLOGICAL), ranibizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03834753?
This trial is sponsored by Outlook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03834753 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
COMPLETED · Phase 3
-
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
COMPLETED · Phase 3
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
COMPLETED · Phase 3
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
Explore more on PlainTrial
Age-related Macular Degeneration
All registered trials for this condition
Neovascular Age-related Macular Degeneration
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.